Page 4 - Analyst Event News Today

Investegate announcements from Advanced Oncotherapy, Investor / Analyst Event Update

Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24Company reiterates advance purchase agreements for expected delivery in 2022 of approximately

/PRNewswire/ -- The prestigious international publication Institutional Investor recognized Grupo Financiero Banorte as the "Most Honored Company" in Mexico in...

First quarter 2022 revenues of $6.1 billion; GAAP net-income of $3.7 billion and GAAP diluted EPS of $8.58Moderna reiterates its 2022 signed advance purchase agreements of approximately $21 billionCompany

Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29Moderna

Press release content from Accesswire. The AP news staff was not involved in its creation.

NKTR earnings call for the period ending September 30, 2021.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody...

Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates Read full article Oops! SARS-CoV-2 Variant Booster Program Update : Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants TeenCOVE Study Update : Initial analysis of the Phase 2/3 TeenCOVE study of mRNA-1273 showed vaccine efficacy against COVID-19 of 9...